Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Argus Health
McKinsey
Julphar
Johnson and Johnson
US Army
Colorcon
Cantor Fitzgerald
Daiichi Sankyo

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,017,928

« Back to Dashboard

Title: Retroviral protease inhibiting compounds
Abstract:A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing Leung (Gurnee, IL), Zhao; Chen (Gurnee, IL), Sowin; Thomas J. (Grayslake, IL), Reno; Daniel S. (Kenosha, WI), Haight; Anthony R. (Park City, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Oct 06, 1997
Application Number:08/944,351
Claims:1. A method for treating a retroviral infection in a mammal comprising administering to said mammal:

(a) an effective amount of a first retroviral protease inhibitor; and

(b) an effective amount of a second retroviral protease inhibitor wherein said second retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to said first retroviral protease inhibitor;

wherein said first retroviral protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane and said second retroviral protease inhibitor is N-tert-Butyl decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2-quinolylcarbonyl)-L-asparag inyl)amino)butyl)-(4aR,8aS)-isoquinoline-3(S)-carboxamide.

2. A method for treating a retroviral infection in a mammal comprising administering to said mammal:

(a) an effective amount of a first retroviral protease inhibitor; and

(b) an effective amount of a second retroviral protease inhibitor wherein said second retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to said first retroviral protease inhibitor;

wherein said first retroviral protease inhibitor is N-tert-Butyl decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2-quinolylcarbonyl)-L-asparag inyl)amino)butyl)-(4aR,8aS)-isoquinoline-3(S)-carboxamide and said second retroviral protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane.

3. A method for treating a retroviral infection in a patient comprising:

(a) selecting two retroviral protease inhibitors wherein a second selected retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to a first selected retroviral protease inhibitor; and

(b) administering to said patient an effective amount of each said first and second selected inhibitors; wherein said first retroviral protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane

and said second retroviral protease inhibitor is N-tert-Butyl decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2-quinolylcarbonyl)-L-asparag inyl)amino)butyl)-(4aR,8aS)-isoquinoline-3(S)-carboxamide.

4. A method for treating a retroviral infection in a patient comprising:

(a) selecting two retroviral protease inhibitors wherein a second selected retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to a first selected retroviral protease inhibitor; and

(b) administering to said patient an effective amount of each said first and second selected inhibitors; wherein said first retroviral protease inhibitor is N-tert-Butyl decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2-quinolylcarbonyl)-L-asparag inyl)amino)butyl)-(4aR,8aS)-isoquinoline-3(S)-carboxamide and said second retroviral protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Deloitte
Covington
US Army
Teva
Accenture
Harvard Business School
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.